Generated by AI
I-Mab Sponsored ADR represents American Depositary Receipts (ADRs) for I-Mab, a biopharmaceutical company that focuses on the discovery and development of innovative biotherapeutics. By utilizing ADRs, I-Mab enables U.S. investors to trade its stock on an American exchange, thereby increasing accessibility to its shares and expanding its investor base beyond its home market in China. I-Mab specializes in cutting-edge treatments primarily targeting cancer and autoimmune diseases, advancing a diversified pipeline of monoclonal antibodies and novel bispecific antibodies. The company is committed to addressing medical needs in oncology and immunology through research partnerships and clinical trials. I-Mab's presence as a Sponsored ADR in the U.S. market highlights its role in bridging international pharmaceutical innovations with American capital markets, facilitating increased funding and global collaboration in its pursuit of medical advancements.
Website2440 Research Boulevard
Rockville, MD, 20850
United States
The latest articles about IMAB.
Summary of Oct 17's posts. Generated by AI.
Summary of Aug 1's posts. Generated by AI.
Summary of Apr 25's posts. Generated by AI.
Summary of Apr 20's posts. Generated by AI.
Investors talking about IMAB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.